Table 2.
The list of combining demethylating drugs and immunotherapy under clinical trials
| Demethylating drugs | Immunotherapy | Cancer types | Study Start | Study location | Phase | ClinicalTrials.gov ID |
|---|---|---|---|---|---|---|
| Decitabine | Pembrolizumab | HER2-negative breast cancer | 2017 | United States | Phase 2 | NCT02957968 |
| Decitabine | Pembrolizumab | relapsed, refractory or progressive non-primary CNS solid tumors and lymphomas | 2018 | United States | Early Phase 1 | NCT03445858 |
| Decitabine | Pembrolizumab | Non-small cell lung cancer | 2018 | United States |
Phase 1 Phase 2 |
NCT03233724 |
| Decitabine | Nivolumab | Unresectable or Metastatic Mucosal Melanoma | 2022 | United States |
Phase 1 Phase 2 |
NCT05089370 |
| Decitabine | Tirelizumab | Advanced Esophageal Squamous Cell Carcinoma | 2023 | China | Phase 2 | NCT05638984 |
| Decitabine | Anti-PD-1 antibody | Relapsed or refractory malignancies | 2016 | China |
Phase 1 Phase 2 |
NCT02961101 |
| Decitabine | MBG453; PDR001 | Advanced/metastatic solid tumors | 2015 | United States |
Phase 1 Phase 2 |
NCT02608268 |
| ASTX727 | Nivolumab | Relapsed or Refractory Diffuse Large B-Cell Lymphoma | 2022 | United States | Phase 1 | NCT05272384 |
| ASTX727 | Durvalumab | recurrent or metastatic squamous cell carcinoma of the head and neck | 2017 | United States |
Phase 1 Phase 2 |
NCT03019003 |
| Azacitidine | Pembrolizumab | Relapsed/Refractory Hodgkin's Lymphoma | 2022 | United States | Phase 2 | NCT05355051 |
| Azacitidine | Pembrolizumab | Metastatic Melanoma | 2017 | United States | Phase 2 | NCT02816021 |
| Azacitidine | Pembrolizumab | Chemo-refractory Metastatic Colorectal Cancer | 2015 | United States | Phase 2 | NCT02260440 |
| Azacitidine | Pembrolizumab | Pancreatic Cancer | 2017 | United States | Phase 2 | NCT03264404 |
| Azacitidine | Pembrolizumab | Advanced Solid Tumors | 2017 | United States |
Phase 1 Phase 2 |
NCT02959437 |
| Azacitidine | Nivolumab | Metastatic Non-Small Cell Lung Cancer | 2013 | United States | Phase 2 | NCT01928576 |
| 5-Azacytidine | Nivolumab | Resectable HPV-Associated Head and Neck Squamous Cell Cancer | 2023 | United States | Phase 1 | NCT05317000 |
| CC-486 | Nivolumab | Hodgkin Lymphoma Refractory | 2022 | United States | Phase 1 | NCT05162976 |
| Guadecitabine | Durvalumab | Advanced kidney cancer | 2017 | United States |
Phase 1 Phase 2 |
NCT03308396 |
| Guadecitabine | Atezolizumab | Refractory or Resistant Urothelial Carcinoma | 2017 | United States | Phase 2 | NCT03179943 |